San Diego, United States
Ambrx, founded in 2003 as a spin-out from The Scripps Research Institute, is a clinical stage biopharmaceutical company listed on Nasdaq under the ticker AMAM. Positioning itself as a pioneer and leader in its field, Ambrx employs an innovative expanded genetic code technology platform to develop next-generation antibody drug conjugates (ADCs) and engineered therapies aimed at modulating the immune system.
The company's portfolio highlights two proprietary ADC candidates: ARX517, which targets the prostate-specific membrane antigen (PSMA), and ARX788, focusing on HER2. Both are designed to enhance efficacy and safety across various cancer indications. As Ambrx moves forward with an array of clinical and preclinical programs, its strategic focus on ADCs and protein engineering technology positions it as a significant contender in the biopharmaceutical landscape, offering promising investment potential in targeted cancer therapies.
